



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



AZD 3293

Item No. 24934

CAS Registry No.: 1383982-64-6
Formal Name: (1 α ,1'R,4 β)-4-methoxy-5''-methyl-6'-[5-(1-propyn-1-yl)-3-pyridinyl]-dispiro[cyclohexane-1,2'-[2H]indene-1'(3'H),2''-[2H]imidazol]-4''-amine
Synonyms: Lanabecestat, LY3314814
MF: C₂₆H₂₈N₄O
FW: 412.5
Purity: \geq 98%
UV/Vis.: λ_{max} : 241 nm
Supplied as: A solid
Storage: -20°C
Stability: \geq 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AZD 3293 is supplied as a solid. A stock solution may be made by dissolving the AZD 3293 in the solvent of choice, which should be purged with an inert gas. AZD 3293 is soluble in ethanol and DMSO.

Description

AZD 3293 is an inhibitor of β -secretase 1 (BACE1) and BACE2 (K_i s = 0.4 and 0.8 nM, respectively).¹ It is selective for BACE1 and BACE2 over cathepsin D, γ -secretase, and human-ether-a-go-go (hERG; IC_{50} s = 3,797, >25,000, and 4,700 nM, respectively). AZD 3293 inhibits the secretion of amyloid- β (1-40) (A β 40) in primary mouse and guinea pig neuronal cultures (IC_{50} s = 0.61 and 0.31 nM, respectively), as well as in SH-SY5Y cells overexpressing human amyloid precursor protein (APP; IC_{50} = 0.08 nM). *In vivo*, AZD 3293 (50, 100, and 200 μ mol/kg) reduces plasma and brain levels of A β 40 and brain levels of A β 42 in mice.

Reference

1. Eketjäll, S., Janson, J., Kaspersson, K., *et al.* AZD3293: A novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics. *J. Alzheimers Dis.* **50(4)**, 1109-1123 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM